ReviewCurrent opinion in rheumatology2025
Molecular imaging of psoriatic arthritis.
Review in Current opinion in rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewPsoriatic arthritis (PsA) is a chronic inflammatory disease associated with psoriasis. Conventional imaging techniques are used to diagnose the disease and detect long-term structural changes. This review will assess molecular imaging in PsA, to evaluate its potential additive value over conventional and advanced anatomical imaging methods (e.g. ultrasound and MRI). RECENT
findingsCurrent research is primarily focused on the molecular imaging technique PET/computed tomography (PET/CT) imaging, in which different tracers have been investigated. Fluorodeoxyglucose (FDG) can visualize disease activity and subclinical inflammation. New tracers targeting inflammatory sites have also been studied, such as FAPI (fibroblast activation protein inhibitor). Moreover, NaF (sodium fluoride) shows promise for imaging of new bone formation. Next to PET/CT, also fluorescence imaging and multispectral optoacoustic tomography have been investigated in the context of PsA. SUMMARY: Molecular imaging techniques hold promise for early diagnosis, monitoring and management of PsA. Future research is needed to define the role of molecular imaging relative to conventional and anatomical imaging techniques in patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.